ADR Biomedical Holdings Inc.
Stock Price Chart
2026/07/21 UpdatedPrice Trend
2026/07/21 UpdatedPrice & Trading Details
2026/07/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/07/01Dividend History
Updated 2026/07/19| Year | Dividend | Change |
|---|---|---|
| 2020 | ¥10 | -50.0% |
| 2019 | ¥20 | +100.0% |
| 2018 | ¥10 | - |
Financial Performance
2026/07/19 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,145M | ¥1,560M | ¥122M | ¥51M |
| Gross Profit | ¥1,269M | ¥1,293M | -¥6M | ¥11M |
| Operating Income | -¥794M | -¥773M | -¥807M | -¥906M |
| Pretax Income | -¥1,037M | -¥857M | -¥2,071M | -¥379M |
| Net Income | -¥1,060M | ¥138M | -¥2,140M | -¥397M |
| EPS | -¥118.71 | ¥15.42 | -¥239.70 | - |
| Operating Margin | -37.04% | -49.52% | -660.28% | -1,777.23% |
| Balance Sheet | ||||
| Total Assets | ¥14,092M | ¥5,816M | ¥3,538M | ¥368M |
| Total Equity | ¥2,653M | ¥2,791M | ¥631M | ¥22M |
| Total Liabilities | ¥11,439M | ¥3,026M | ¥2,907M | ¥346M |
| Cash | ¥1,123M | ¥1,038M | ¥256M | ¥126M |
| Interest-bearing Debt | ¥8,507M | ¥2,472M | ¥2,648M | ¥0M |
| Equity Ratio | 18.82% | 47.98% | 17.82% | 5.98% |
| D/E Ratio | 3.21 | 0.89 | 4.20 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥40M | -¥1,152M | -¥987M | -¥785M |
| Investing CF | -¥283M | ¥8,690M | ¥23M | ¥2,979M |
| Financing CF | ¥294M | -¥7,173M | ¥172M | -¥2,322M |
| Free CF | -¥198M | -¥1,168M | -¥995M | -¥785M |
| Efficiency | ||||
| ROE | -39.96% | 4.95% | -339.41% | -1,801.98% |
| ROA | -7.52% | 2.38% | -60.50% | -107.84% |
Latest IR Information
-
ADR BioMedical Holdings Mid-Term Management Plan 2026-2028
ADR BioMedical Holdings has formulated a mid-term management plan for 2026-2028, aiming to expand sales from 750 million yen to 4.06 billion yen. The company plans to focus on new businesses and research & development to expand recurring revenue streams.
Read more -
Notice of Start of Medical Device Rental Business
Read more -
Notice on the Progress of Insurance Coverage Procedures for the Medical Device "Celeration Sels Therapy Kit SUI" for Male Stress Urinary Incontinence Treatment
Read more -
Notice Regarding the Commencement of the NeoCella Breeding Mare Business
Read more
Latest News (5 items)
Company Information
About
ADR Biomedical Holdings Inc. engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence; ECCL-50 to treat liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, meniscus repair, stress urinary incontinence scleroderma, vocal cord repair, liver cirrhosis, etc. In addition, it invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services. The company was formerly known as ADR120S, Inc. and changed its name to ADR Biomedical Holdings Inc. in July 2026. ADR Biomedical Holdings Inc. was incorporated in 2004 and is headquartered in Chiyoda, Japan.
